# A Clinical Trial of LBL-034 in Patients With Relapsed Refractory Multiple Myeloma

Source: https://onco.cc/trials/nct06049290/  
OnCo record `nct06049290` (Trial). Data CC BY-NC 4.0, attribute "Data from OnCo (onco.cc)"; commercial use needs a licence.

## TL;DR

A phase 1/2 trial of LBL-034 for Injection in multiple myeloma, run by Nanjing Leads Biolabs Co.,Ltd, now recruiting.

## Summary

A Clinical Trial of LBL-034 in Patients With Relapsed Refractory Multiple Myeloma is a phase 1/2 interventional study registered as NCT06049290 by Nanjing Leads Biolabs Co.,Ltd, with 342 participants planned, started 2023-10-20 and due to reach its primary completion in 2026-10-20. Interventions recorded: LBL-034 for Injection.

## Fields

- Kind: Trial
- Status: recruiting
- Last checked: 2026-09-16
- Tags: pipeline; ctgov-ingest
- Registry id: NCT06049290
- Phase: 1/2
- Setting: A Multicenter, Open-label, Phase I/II Clinical Study to Evaluate the Safety, Tolerability, Pharmacokinetics, and Efficacy of LBL-034 in Patients With Relapsed/Refractory Multiple Myeloma
- Sponsor: Nanjing Leads Biolabs Co.,Ltd
- Enrolled: 342

## Sources

- ClinicalTrials.gov NCT06049290: https://clinicaltrials.gov/study/NCT06049290

## Connected records

- cancers: [Multiple myeloma](https://onco.cc/cancers/multiple-myeloma/)
- companies: [Nanjing Leads Biolabs](https://onco.cc/companies/nanjing-leads-biolabs/)

---
JSON: https://onco.cc/api/v1/entities/nct06049290.json